Search

Your selection

Clear all

Filter by content type

Filter by content year

News

Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

December 21, 2023 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results

November 2, 2023 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

November 2, 2023 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2

October 26, 2023 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19

October 11, 2023 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference

September 21, 2023 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate

September 6, 2023 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results

August 3, 2023 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart to Host Second Quarter 2023 Business Update and Financial Results Conference Call on August 3

July 27, 2023 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

July 6, 2023 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
Scroll to Top